Lutetium-177 edotreotide (ITM-11)_Dosage, benefits & legal status

The mechanism is shared with two other cards here. What distinguishes this one is a single chemical group that letter notation cannot show, and the reason that matters is that the most repeated comparison between these drugs rests on data from neither of them.

1. 01
   The peptide is a homing device, not the drug

   Well-differentiated neuroendocrine tumors carry far more somatostatin receptor 2 on their surface than healthy tissue does. Octreotide, a short cyclic peptide already covered here, binds that receptor tightly. Attach a chelator to its free end, load the chelator with a radioactive metal, and the peptide carries that metal to the tumor and is pulled inside with the receptor. The peptide itself contributes almost nothing therapeutically; it is the delivery vehicle.
2. 02
   Lutetium-177 does the damage, over a short distance

   Lutetium-177 decays with a half-life of 6.647 days, emitting beta particles up to 0.498 MeV that travel at most 2.2 mm in tissue and 0.67 mm on average. That range covers the cell that absorbed the drug and perhaps a few dozen neighbors, and that is the point: tumor cells that happen to lack the receptor are still irradiated by their neighbors. It also emits gamma rays at 0.208 and 0.113 MeV, allowing imaging and making a vial a regulated radiation source.
3. 03
   The one residue, and why nobody can see it

   This drug and the approved Lutathera differ at the eighth of eight residues: threoninol here, threonine there. An alcohol against a carboxylic acid. In the single-letter notation this site uses, both read FCYWKTCT, so the difference is invisible. The molecular formulas settle it without relying on anyone's prose: C65H92N14O18S2 at 1421.6437 for this ligand against C65H90N14O19S2 at 1435.6272 for the other. That is minus two hydrogens, plus one oxygen, plus 13.98 Da, with identical carbon, nitrogen and sulfur counts: exactly one alcohol oxidized to an acid and nothing else.
4. 04
   The affinity claim that has been carried across metals

   The widely repeated statement that dotatate binds about ten times tighter traces to one 2000 paper: sst2 IC50 of 2.5 nM for gallium-DOTATOC against 0.2 nM for gallium-DOTATATE, a 12.5-fold ratio, with the approved gallium-68 edotreotide label independently reporting 2.5 plus or minus 0.5 nM. The problem is that both therapeutics are lutetium complexes, and that paper reports no lutetium-labeled value at all while showing that the metal itself shifts affinity substantially. So a gallium measurement is being quoted about lutetium drugs. Nor has the comparison been tested clinically: two literature sweeps found no head-to-head trial, and the largest pooled analysis mixes patients on either agent while its own authors note the absence of formal comparative analysis.
5. 05
   How the three cards actually relate

   Worth holding straight, because the pattern is symmetrical. Against lutetium-177 dotatate, this drug changes the peptide and keeps the radionuclide. RYZ101, also covered here, is the same peptide as dotatate with a different radionuclide, actinium-225 rather than lutetium-177. One axis each.